Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin.

Lobert VH, Bruun J, Abrahamsen H, Lothe RA, Stenmark H, Kolberg M, Campsteijn C.

EMBO Rep. 2013 Jan;14(1):10-1. doi: 10.1038/embor.2012.188. Epub 2012 Dec 11. No abstract available.

2.

Response: 'Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin'.

McIntush EW.

EMBO Rep. 2013 Jun;14(6):494-6. doi: 10.1038/embor.2013.68. Epub 2013 May 17. No abstract available.

3.

Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.

Suljagic M, Laurenti L, Tarnani M, Alam M, Malek SN, Efremov DG.

Leukemia. 2010 Dec;24(12):2063-71. doi: 10.1038/leu.2010.201. Epub 2010 Sep 23.

PMID:
20861921
4.

Reproducibility crisis: Blame it on the antibodies.

Baker M.

Nature. 2015 May 21;521(7552):274-6. doi: 10.1038/521274a. No abstract available.

PMID:
25993940
5.

Localization of protein Ser/Thr phosphatase 5 in rat brain.

Bahl R, Bradley KC, Thompson KJ, Swain RA, Rossie S, Meisel RL.

Brain Res Mol Brain Res. 2001 Jun 20;90(2):101-9.

PMID:
11406288
6.

Detection of PHLPP1α/β in human and mouse brain by different anti-PHLPP1 antibodies.

Jackson TC, Bayir H, Ikonomovic MD, Janesko-Feldman K, Mi Z, Gao T, Jackson EK, Kochanek PM.

Sci Rep. 2015 Apr 1;5:9377. doi: 10.1038/srep09377.

7.

[Effect of phosphatase PHLPP1 gene transfer on the proliferation of human umbilical vein endothelial cells].

Wu XL, Yang DY, Yan W, Shang AJ, Lu CY, Xu HB, Wang SW.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1298-300. Chinese.

8.

The expression patterns and correlations of chibby, β-catenin, and DNA methyltransferase-1 and their clinicopathological significance in lung cancers.

Xu HT, Li QC, Dai SD, Xie XM, Liu DI, Wang EH.

APMIS. 2011 Nov;119(11):750-8. doi: 10.1111/j.1600-0463.2011.02799.x. Epub 2011 Aug 22.

PMID:
21995627
9.

Non-specific antibody interactions.

Nybo K.

Biotechniques. 2012 May;52(5):305-6. doi: 10.2144/000113849. No abstract available.

10.

PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.

Saavedra A, García-Martínez JM, Xifró X, Giralt A, Torres-Peraza JF, Canals JM, Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E.

Cell Death Differ. 2010 Feb;17(2):324-35. doi: 10.1038/cdd.2009.127. Epub 2009 Sep 11.

11.

Frequent nuclear expression of beta-catenin protein but rare beta-catenin mutation in pulmonary sclerosing haemangioma.

Chiang PM, Yuan RH, Hsu HC, Mao TL, Hu RH, Lai PL, Jeng YM.

J Clin Pathol. 2008 Mar;61(3):268-71. Epub 2007 Aug 10.

PMID:
17693578
12.

β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.

Lacroix-Triki M, Geyer FC, Lambros MB, Savage K, Ellis IO, Lee AH, Reis-Filho JS.

Mod Pathol. 2010 Nov;23(11):1438-48. doi: 10.1038/modpathol.2010.141. Epub 2010 Aug 6.

13.

Artifact occurring during combined in situ hybridization and immunocytochemistry analysis because of positive chemography.

Häkkinen T, Ylä-Herttuala S.

Biotechniques. 1998 May;24(5):730-2. No abstract available.

PMID:
9591116
14.

Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.

Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H, Zhou C, Zhang G, Quan L, Bai J, Xu N.

Br J Cancer. 2006 Mar 13;94(5):686-91.

15.

beta-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome.

de Castro J, Gamallo C, Palacios J, Moreno-Bueno G, Rodríguez N, Feliu J, González-Barón M.

Virchows Arch. 2000 Dec;437(6):599-604.

PMID:
11193470
16.

Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Hirano I, Nakamura S, Yokota D, Ono T, Shigeno K, Fujisawa S, Shinjo K, Ohnishi K.

J Biol Chem. 2009 Aug 14;284(33):22155-65. doi: 10.1074/jbc.M808182200. Epub 2009 Mar 4.

17.

Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.

Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O.

J Pathol. 2009 May;218(1):86-94. doi: 10.1002/path.2514.

PMID:
19197950
18.
19.

Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors.

Takeda K, Kinoshita I, Shimizu Y, Ohba Y, Itoh T, Matsuno Y, Shichinohe T, Dosaka-Akita H.

BMC Cancer. 2008 Nov 8;8:328. doi: 10.1186/1471-2407-8-328.

20.

Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.

Umbreit C, Aderhold C, Faber A, Sommer JU, Sauter A, Hofheinz RD, Stern-Sträter J, Hoermann K, Schultz JD.

Anticancer Res. 2013 Jun;33(6):2457-65.

PMID:
23749896

Supplemental Content

Support Center